Across TCGA pan-cancer cohorts, KRTAP13-2 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated KRTAP13-2 data layer compared with 6 for mutation status.
The strongest signal is observed in mesothelioma (MESO), where higher KRTAP13-2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP13-2 expression acts as an unfavorable survival marker, although some lineages such as PAAD and UCEC show a favorable association.
MESO, COAD, and UVM are the cancer types where KRTAP13-2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.